Depression and Anxiety Trial, Recruiting NCT05866575 Sponsor: Centre Hospitalier St Anne Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT05866575
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with depression:

  • People who have been diagnosed with major depressive disorder (a single episode or recurring episodes) according to standard diagnostic guidelines
  • People whose depression symptoms score at least 24 on a standard depression rating scale called the MADRS, indicating moderate to severe depression
  • People who need to start a new course of treatment for their depression
  • People who have either never taken antidepressant medication for their current episode, or who have stopped long enough that previous medication is no longer affecting their system
  • People who have valid health insurance coverage

For healthy volunteers:

  • People who have valid health insurance coverage

Who may not be able to join:

For people with depression:

  • People whose depression has not responded well to at least two different antidepressant medications taken at the right dose for long enough (known as treatment-resistant depression)
  • People who have already tried the medications escitalopram or vortioxetine during their current episode, or for whom either of these medications is medically unsuitable
  • People who have a diagnosis of persistent depressive disorder, bipolar disorder, schizophrenia, a neurodevelopmental condition, an active substance use disorder (other than tobacco use), or a severe personality disorder that could make regular follow-up difficult (as judged by the trial doctor)
  • People with a history of a neurological condition such as Parkinson's disease or dementia
  • People for whom MRI scans are not safe, including those who are pregnant, experience severe claustrophobia, or have certain metal implants in their body
  • Women who are pregnant or breastfeeding
  • People who are currently hospitalised involuntarily or under a legal protection order

For healthy volunteers:

  • People who have a diagnosis of persistent depressive disorder, bipolar disorder, schizophrenia, a neurodevelopmental condition, an active substance use disorder (other than tobacco use), or a severe personality disorder that could make regular follow-up difficult (as judged by the trial doctor)
  • People with a history of a neurological condition such as Parkinson's disease or dementia
  • People for whom MRI scans are not safe, including those who are pregnant, experience severe claustrophobia, or have certain metal implants in their body
  • Women who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0033683714083

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier St Anne
Registry
ClinicalTrials.gov
Start date
12 September 2023
Est. completion
12 October 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Prediction of the therapeutic response (MADRS score) 28 days after the introduction of the antidepressant strategy (V3) based on the early changes (differences between V1 and V2) of the computational phenotype of depressed patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov